


# New theranostic agents show efficacy in prostate cancer treatment in preclinical studies

July 13 2020



Panel A shows PET images (coronal slices) of  $^{124}\text{I}$ -MSK-PSMA1 in mice bearing PC3-PIP xenografts on the right shoulder at 24, 48 and 168 hours after administration, demonstrating accumulation and retention of activity in the tumor. Panel B shows ex vivo biodistribution data of  $^{131}\text{I}$ -MSK-PSMA1 in mice bearing PC3-PIP xenografts at 1, 2, 6 and 24 hours after administration. Credit:

Kalidindi TM, et al., Pillarsetty Lab, MSKCC, New York, NY.

Researchers have developed a new pair of agents that show exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies. The agents, which target prostate-specific membrane antigen (PSMA), can be easily and economically synthesized without specialized equipment. This research was presented at the Society of Nuclear Medicine and Molecular Imaging's 2020 Annual Meeting on July 11-14.

PSMA is highly overexpressed in both primary and [metastatic prostate cancer](#), making it a leading target for the development of radiopharmaceuticals. Iodine has several easily available isotopes with long half-lives that can be used for single-photon emission computed tomography (SPECT), positron emission tomography (PET) or therapy. However, currently available radioiodinated PSMA-targeting radiopharmaceuticals require multiple steps for production, which reduces their yield and poses significant challenges for producing therapeutic doses.

To address this issue, researchers at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York, developed the novel radioiodinated PSMA-targeting radiopharmaceutical <sup>124</sup>I/<sup>131</sup>I-MSK-PSMA1. "We were motivated by the fact that <sup>131</sup>I is widely available, economical, can be used for [diagnostic imaging](#) and has demonstrated efficacy as a therapeutic agent. Our goal was to develop a radiopharmaceutical that can be produced very easily in high yields and high purity without requiring specialized equipment," said Dr. Kishore Pillarsetty, a radiochemist at MSK and senior author on the research. "<sup>124</sup>I/<sup>131</sup>I-MSK-PSMA1 is the result of this search."

To demonstrate its efficacy, researchers synthesized  $^{124}\text{I}/^{131}\text{I}$ -MSK-PSMA1 and performed *in vitro* and *in vivo* studies. *In vitro* saturation binding assays were performed in [prostate cancer](#) cells, which were later harvested and counted for radioactivity using a gamma counter. *In vivo* PET imaging and biodistribution studies were performed on mice bearing prostate cancer xenografts.

The study indicates that  $^{124}\text{I}/^{131}\text{I}$ -MSK-PSMA1 can be produced in [high yields](#) without generating volatile byproducts, eliminating the need for high-pressure liquid chromatography purification. The *in vitro* and *in vivo* studies in prostate cancer cell and tumor xenograft models indicate high specificity, favorable pharmacokinetics and rapid clearance from non-target tissue.

"The exceptional tumor targeting and clearance from non-PSMA-expressing tissues make  $^{124}\text{I}$ -MSK-PSMA1 an excellent PET imaging agent and the corresponding  $^{131}\text{I}$ -MSK-PSMA1 a highly potent radiotherapeutic agent," said lead author Teja Muralidar Kalidindi, a senior research technician at MSK. "Because the diagnostic and therapeutic isotopes are chemically identical, we can precisely estimate the dose delivered to the tumor and other organs and personalize the dose to achieve the goals of precision medicine. We believe that  $^{124}\text{I}/^{131}\text{I}$ -MSK-PSMA1 has the potential to become part of the armamentarium available to the nuclear medicine and molecular imaging community for the diagnosis and treatment of metastatic castration-resistant prostate cancer patients."

Researchers are currently working with nuclear medicine clinicians to translate these findings into the first-in-human clinical trial for  $^{124}\text{I}/^{131}\text{I}$ -MSK-PSMA1. Additionally, the team plans to develop a kit formulation that will facilitate on-demand, onsite production to ensure that the radiopharmaceutical is available to the worldwide research community.

Provided by Society of Nuclear Medicine and Molecular Imaging

Citation: New theranostic agents show efficacy in prostate cancer treatment in preclinical studies (2020, July 13) retrieved 27 April 2024 from

<https://medicalxpress.com/news/2020-07-theranostic-agents-efficacy-prostate-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.